Cefpodoxime Proxetil is indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:

Lower respiratory tract infections:

Community-acquired pneumonia caused by S. pneumoniae or H. influenzae (including beta-lactamase-producing strains).
Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only) or M. catarrhalis.
Upper respiratory tract infections:
Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis. Acute otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains) or Moraxella catarrhalis. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.
Skin and skin structure infections:

Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes.

Urinary tract infections:

Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, proteus mirabilis or Staphylococcus saprophyticus.
Sexually transmitted diseases:
Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
Acute uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

Dosage & Administration

Adults: 200 mg as a single dose or 100-200 mg twice daily for 5-14 days depending on the severity of the infection.

Adults (age 12 years and older):

Type of Infection


Total Daily Dose


Dose Frequency



Pharyngitis and/or tonsillitis


200 mg


100 mg 12 hourly


5 to 10 days

Acute community- acquired









400 mg


200 mg 12 hourly


14 days

Acute bacterial exacerbations of







chronic bronchitis


400 mg


200 mg 12 hourly


10 days

Uncomplicated gonorrhea







(men and women) and rectal







gonococcal infections (women)


200 mg


Single dose



Skin and skin structure


800 mg


400 mg 12 hourly


7 to 14 days

Acute maxillary sinusitis


400 mg


200 mg 12 hourly


10 days

Uncomplicated urinary tract infection


200 mg


100 mg 12 hourly


7 days


Infants and paediatric patients (age 2 months through 12 years):




15 days to 6 months

4 mg/kg body weight every 12 hours

6 months to 2 years

40 mg every 12 hours

3 years to 8 years

80 mg every 12 hours

Over 9 years

100 mg every 12 hours



Direction for Reconstitution
Cefomin® suspension: Shake the bottle before adding water. Then add 30 ml of boiled and cool water to the bottle. For ease of preparation, add the water in two portions. Shake the bottle gently until the powder is dissolved properly. Shake the bottle well before each


In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of Cefpodoxime should be reduced because high and prolonged serum antibiotic concentration can occur in such individuals following usual doses. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics. As with other antibiotics, prolonged use of Cefpodoxime may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken. Use in pregnancy: Cefpodoxime is in pregnancy category B. There are no adequate & well-controlled studies in pregnant
women. So this drug should be used during pregnancy only if clearly needed. Use in lactation: Cefpodoxime is excreted in human milk. Because of the potential for serious reactions in nursing infants, a decision should be made whether to discontinue nursing or
to discontinue the drug, taking into account the importance of the drug to the mother.

Product Details

Related Products


Antibiotics & Antiviral


Antibiotics & Antiviral


Antibiotics & Antiviral


Antibiotics & Antiviral